Last reviewed · How we verify
Intraoperative Injection of Carbon Nanoparticles
Intraoperative Injection of Carbon Nanoparticles is a Diagnostic imaging agent / Surgical tracer Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University. It is currently in Phase 3 development for Sentinel lymph node identification and biopsy in cancer surgery.
Carbon nanoparticles injected intraoperatively accumulate in lymph nodes to enable sentinel lymph node identification and removal during cancer surgery.
Carbon nanoparticles injected intraoperatively accumulate in lymph nodes to enable sentinel lymph node identification and removal during cancer surgery. Used for Sentinel lymph node identification and biopsy in cancer surgery.
At a glance
| Generic name | Intraoperative Injection of Carbon Nanoparticles |
|---|---|
| Sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
| Drug class | Diagnostic imaging agent / Surgical tracer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carbon nanoparticles serve as a tracer agent that preferentially drains to and concentrates in sentinel lymph nodes, the first nodes to which cancer may spread. By visualizing these nodes intraoperatively through their black coloration, surgeons can identify and selectively remove them for pathological examination, improving staging accuracy and reducing unnecessary lymph node dissection.
Approved indications
- Sentinel lymph node identification and biopsy in cancer surgery
Common side effects
- Local injection site reactions
- Allergic reactions
Key clinical trials
- Deep Learning-Based Intraoperative Dual-tracer Video Analysis of Sentinel Lymph Node Mapping for Metastasis Prediction in cN0 Papillary Thyroid Carcinoma
- A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. (PHASE3)
- Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraoperative Injection of Carbon Nanoparticles CI brief — competitive landscape report
- Intraoperative Injection of Carbon Nanoparticles updates RSS · CI watch RSS
- Second Affiliated Hospital of Xi'an Jiaotong University portfolio CI
Frequently asked questions about Intraoperative Injection of Carbon Nanoparticles
What is Intraoperative Injection of Carbon Nanoparticles?
How does Intraoperative Injection of Carbon Nanoparticles work?
What is Intraoperative Injection of Carbon Nanoparticles used for?
Who makes Intraoperative Injection of Carbon Nanoparticles?
What drug class is Intraoperative Injection of Carbon Nanoparticles in?
What development phase is Intraoperative Injection of Carbon Nanoparticles in?
What are the side effects of Intraoperative Injection of Carbon Nanoparticles?
Related
- Drug class: All Diagnostic imaging agent / Surgical tracer drugs
- Manufacturer: Second Affiliated Hospital of Xi'an Jiaotong University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Sentinel lymph node identification and biopsy in cancer surgery
- Compare: Intraoperative Injection of Carbon Nanoparticles vs similar drugs
- Pricing: Intraoperative Injection of Carbon Nanoparticles cost, discount & access